{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:17:21Z","timestamp":1791317841056,"version":"4.3.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T00:00:00Z","timestamp":1408492800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1007\/s40263-014-0193-z","type":"journal-article","created":{"date-parts":[[2014,8,19]],"date-time":"2014-08-19T11:29:52Z","timestamp":1408447792000},"page":"1191-1203","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Health-Related Quality of Life and Functional Outcomes from a Randomized-Withdrawal Study of Long-Term Lisdexamfetamine Dimesylate Treatment in Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder"],"prefix":"10.1007","volume":"28","author":[{"given":"Tobias","family":"Banaschewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mats","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Lecendreux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Zuddas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Adeyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hodgkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liza A.","family":"Squires","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David R.","family":"Coghill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,8,20]]},"reference":[{"key":"193_CR1","doi-asserted-by":"crossref","first-page":"317","DOI":"10.2147\/NDT.S9749","volume":"6","author":"M Pennick","year":"2010","unstructured":"Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317\u201327.","journal-title":"Neuropsychiatr Dis Treat."},{"key":"193_CR2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/1753-2000-3-17","volume":"3","author":"SB Wigal","year":"2009","unstructured":"Wigal SB, Kollins SH, Childress AC, Squires L. A 13-h laboratory school study of lisdexamfetamine dimesylate in school-aged children with attention-deficit\/hyperactivity disorder. Child Adolesc Psychiatry Ment Health. 2009;3:17.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"193_CR3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1186\/1744-9081-6-34","volume":"6","author":"T Wigal","year":"2010","unstructured":"Wigal T, Brams M, Gasior M, Gao J, Squires L, Giblin J. Randomized, double-blind, placebo-controlled, crossover study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: novel findings using a simulated adult workplace environment design. Behav Brain Funct. 2010;6:34.","journal-title":"Behav Brain Funct."},{"key":"193_CR4","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/S0149-2918(07)80083-X","volume":"29","author":"J Biederman","year":"2007","unstructured":"Biederman J, Krishnan S, Zhang Y, McGough JJ, Findling RL. Efficacy and tolerability of lisdexamfetamine dimesylate (NRP-104) in children with attention-deficit\/hyperactivity disorder: a phase III, multicenter, randomized, double-blind, forced-dose, parallel-group study. Clin Ther. 2007;29:450\u201363.","journal-title":"Clin Ther."},{"key":"193_CR5","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaac.2011.01.007","volume":"50","author":"RL Findling","year":"2011","unstructured":"Findling RL, Childress AC, Cutler AJ, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Efficacy and safety of lisdexamfetamine dimesylate in adolescents with attention-deficit\/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2011;50:395\u2013405.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"193_CR6","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.4088\/JCP.v69n0903","volume":"69","author":"LA Adler","year":"2008","unstructured":"Adler LA, Goodman DW, Kollins SH, Weisler RH, Krishnan S, Zhang Y, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder. J Clin Psychiatry. 2008;69:1364\u201373.","journal-title":"J Clin Psychiatry."},{"key":"193_CR7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1016\/j.euroneuro.2012.11.012","volume":"23","author":"D Coghill","year":"2013","unstructured":"Coghill D, Banaschewski T, Lecendreux M, Soutullo C, Johnson M, Zuddas A, et al. European, randomized, phase 3 study of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder. Eur Neuropsychopharmacol. 2013;23:1208\u201318.","journal-title":"Eur Neuropsychopharmacol."},{"key":"193_CR8","doi-asserted-by":"crossref","first-page":"977","DOI":"10.4088\/JCP.11m07430","volume":"73","author":"M Brams","year":"2012","unstructured":"Brams M, Weisler R, Findling RL, Gasior M, Hamdani M, Ferreira-Cornwell MC, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in adults with attention-deficit\/hyperactivity disorder: randomized withdrawal design. J Clin Psychiatry. 2012;73:977\u201383.","journal-title":"J Clin Psychiatry."},{"key":"193_CR9","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.jaac.2014.01.017","volume":"53","author":"DR Coghill","year":"2014","unstructured":"Coghill DR, Banaschewski T, Lecendreux M, Johnson M, Zuddas A, Anderson CS, et al. Maintenance of efficacy of lisdexamfetamine dimesylate in children and adolescents with attention-deficit\/hyperactivity disorder: randomized-withdrawal study design. J Am Acad Child Adolesc Psychiatry. 2014;53:647\u201357.e1.","journal-title":"J Am Acad Child Adolesc Psychiatry."},{"key":"193_CR10","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2147\/TCRM.S30762","volume":"9","author":"DW Goodman","year":"2013","unstructured":"Goodman DW. Sustained treatment effect in attention-deficit\/hyperactivity disorder: focus on long-term placebo-controlled randomized maintenance withdrawal and open-label studies. Ther Clin Risk Manag. 2013;9:121\u201330.","journal-title":"Ther Clin Risk Manag."},{"key":"193_CR11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1753-2000-3-1","volume":"3","author":"E Parens","year":"2009","unstructured":"Parens E, Johnston J. Facts, values, and attention-deficit hyperactivity disorder (ADHD): an update on the controversies. Child Adolesc Psychiatry Ment Health. 2009;3:1.","journal-title":"Child Adolesc Psychiatry Ment Health."},{"key":"193_CR12","doi-asserted-by":"crossref","DOI":"10.1176\/appi.books.9780890425596","volume-title":"Neurodevelopmental disorders. Diagnostic and statistical manual of mental disorders","author":"American Psychiatric Association","year":"2013","unstructured":"American Psychiatric Association. Neurodevelopmental disorders. Diagnostic and statistical manual of mental disorders. 5th ed. Arlington: American Psychiatric Publishing; 2013.","edition":"5"},{"key":"193_CR13","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s40263-013-0095-5","volume":"27","author":"T Banaschewski","year":"2013","unstructured":"Banaschewski T, Soutullo C, Lecendreux M, Johnson M, Zuddas A, Hodgkins P, et al. Health-related quality of life and functional outcomes from a randomized, controlled study of lisdexamfetamine dimesylate in children and adolescents with attention deficit hyperactivity disorder. CNS Drugs. 2013;27:829\u201340.","journal-title":"CNS Drugs."},{"issue":"Suppl 1","key":"193_CR14","doi-asserted-by":"crossref","first-page":"I63","DOI":"10.1007\/s00787-006-1009-6","volume":"15","author":"AW Riley","year":"2006","unstructured":"Riley AW, Coghill D, Forrest CB, Lorenzo MJ, Ralston SJ, Spiel G. Validity of the health-related quality of life assessment in the ADORE study: Parent Report Form of the CHIP-Child Edition. Eur Child Adolesc Psychiatry. 2006;15(Suppl 1):I63\u201371.","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"193_CR15","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1097\/01.mlr.0000114909.33878.ca","volume":"42","author":"AW Riley","year":"2004","unstructured":"Riley AW, Forrest CB, Starfield B, Rebok GW, Robertson JA, Green BF. The Parent Report Form of the CHIP-Child Edition: reliability and validity. Med Care. 2004;42:210\u201320.","journal-title":"Med Care."},{"key":"193_CR16","unstructured":"Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Weiss Functional Impairment Rating Scale-Parent Report (WFIRS-P). 2000. http:\/\/www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011WFIRS_P.pdf . Accessed 18 Mar 2013."},{"key":"193_CR17","unstructured":"Canadian Attention Deficit Hyperactivity Disorder Resource Alliance. Weiss Functional Impairment Rating Scale (WFIRS) instructions. 2000. http:\/\/www.caddra.ca\/cms4\/pdfs\/caddraGuidelines2011WFIRSInstructions.pdf . Accessed 14 Oct 2013."},{"key":"193_CR18","unstructured":"European Medicines Agency, Committee for Medicinal Products for Human Use. Guideline on the clinical investigation of medicinal products for the treatment of attention deficit hyperactivity disorder (ADHD). 2010. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2010\/08\/WC500095686.pdf . Accessed 22 Nov 2013."},{"key":"193_CR19","volume-title":"Technical manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0)","author":"AW Riley","year":"2001","unstructured":"Riley AW, Robertson JA, Forrest CB, Green BF, Rebok GW, Starfield B. Technical manual for the Child Health and Illness Profile-Child Edition (CHIP-CE) Parent and Child Report Forms (Version 1.0). Baltimore: Johns Hopkins University; 2001."},{"key":"193_CR20","unstructured":"Riley A, Starfield B, Forrest CB, Green BF, Robertson J, Rajmil L. Child Health and Illness Profile: a comprehensive assessment of health and functioning for children and adolescents. 2007. http:\/\/www.childhealthprofile.org\/index.asp?pageid=49 . Accessed 20 Nov 2013."},{"key":"193_CR21","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.euroneuro.2010.11.007","volume":"21","author":"D Coghill","year":"2011","unstructured":"Coghill D. Pragmatic measures in paediatric psychopharmacology: are we getting it right? Eur Neuropsychopharmacol. 2011;21:571\u201383.","journal-title":"Eur Neuropsychopharmacol."},{"key":"193_CR22","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/j.1469-7610.2009.02008.x","volume":"50","author":"D Coghill","year":"2009","unstructured":"Coghill D, Danckaerts M, Sonuga-Barke E, Sergeant J. Practitioner review: quality of life in child mental health\u2014conceptual challenges and practical choices. J Child Psychol Psychiatry. 2009;50:544\u201361.","journal-title":"J Child Psychol Psychiatry."},{"key":"193_CR23","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s00787-009-0046-3","volume":"19","author":"M Danckaerts","year":"2010","unstructured":"Danckaerts M, Sonuga-Barke EJ, Banaschewski T, Buitelaar J, Dopfner M, Hollis C, et al. The quality of life of children with attention deficit\/hyperactivity disorder: a systematic review. Eur Child Adolesc Psychiatry. 2010;19:83\u2013105.","journal-title":"Eur Child Adolesc Psychiatry."},{"key":"193_CR24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s12402-011-0066-y","volume":"3","author":"A Schacht","year":"2011","unstructured":"Schacht A, Escobar R, Wagner T, Wehmeier PM. Psychometric properties of the quality of life scale Child Health and Illness Profile-Child Edition in a combined analysis of five atomoxetine trials. Atten Defic Hyperact Disord. 2011;3:335\u201349.","journal-title":"Atten Defic Hyperact Disord."},{"key":"193_CR25","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1477-7525-8-78","volume":"8","author":"MD Estrada","year":"2010","unstructured":"Estrada MD, Rajmil L, Serra-Sutton V, Tebe C, Alonso J, Herdman M, et al. Reliability and validity of the Spanish version of the Child Health and Illness Profile (CHIP) Child-Edition, Parent Report Form (CHIP-CE\/PRF). Health Qual Life Outcomes. 2010;8:78.","journal-title":"Health Qual Life Outcomes."},{"key":"193_CR26","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1097\/JCP.0b013e31829c762b","volume":"33","author":"J Fuentes","year":"2013","unstructured":"Fuentes J, Danckaerts M, Cardo E, Puvanendran K, Berquin P, De Bruyckere K, et al. Long-term quality-of-life and functioning comparison of atomoxetine versus other standard treatment in pediatric attention-deficit\/hyperactivity disorder. J Clin Psychopharmacol. 2013;33:766\u201374.","journal-title":"J Clin Psychopharmacol."},{"key":"193_CR27","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1089\/cap.2008.0166","volume":"19","author":"M Maziade","year":"2009","unstructured":"Maziade M, Rouleau N, Lee B, Rogers A, Davis L, Dickson R. Atomoxetine and neuropsychological function in children with attention-deficit\/hyperactivity disorder: results of a pilot study. J Child Adolesc Psychopharmacol. 2009;19:709\u201318.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"193_CR28","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1089\/cap.2011.0018","volume":"21","author":"MA Stein","year":"2011","unstructured":"Stein MA, Waldman ID, Charney E, Aryal S, Sable C, Gruber R, et al. Dose effects and comparative effectiveness of extended release dexmethylphenidate and mixed amphetamine salts. J Child Adolesc Psychopharmacol. 2011;21:581\u20138.","journal-title":"J Child Adolesc Psychopharmacol."},{"key":"193_CR29","doi-asserted-by":"crossref","unstructured":"Epstein JN, Weiss MD. Assessing treatment outcomes in attention-deficit\/hyperactivity disorder: a narrative review. Prim Care Companion CNS Disord. 2012;14. doi: 10.4088\/PCC.11r01336 .","DOI":"10.4088\/PCC.11r01336"},{"key":"193_CR30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1037\/0033-2909.112.1.155","volume":"112","author":"J Cohen","year":"1992","unstructured":"Cohen J. A power primer. Psychol Bull. 1992;112:155\u20139.","journal-title":"Psychol Bull."},{"key":"193_CR31","doi-asserted-by":"crossref","first-page":"843","DOI":"10.2165\/11537450-000000000-00000","volume":"24","author":"D Coghill","year":"2010","unstructured":"Coghill D. The impact of medications on quality of life in attention-deficit hyperactivity disorder: a systematic review. CNS Drugs. 2010;24:843\u201366.","journal-title":"CNS Drugs."},{"key":"193_CR32","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1097\/01.chi.0000125089.35109.81","volume":"43","author":"D Michelson","year":"2004","unstructured":"Michelson D, Buitelaar JK, Danckaerts M, Gillberg C, Spencer TJ, Zuddas A, et al. Relapse prevention in pediatric patients with ADHD treated with atomoxetine: a randomized, double-blind, placebo-controlled study. J Am Acad Child Adolesc Psychiatry. 2004;43:896\u2013904.","journal-title":"J Am Acad Child Adolesc Psychiatry."}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40263-014-0193-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0193-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-014-0193-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T13:12:22Z","timestamp":1551186742000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40263-014-0193-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,20]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["193"],"URL":"https:\/\/doi.org\/10.1007\/s40263-014-0193-z","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,20]]}}}